Ahead of the anticipated 2019 marketing of FDA-approved anticancer biosimilars in the United States, pharmacy benefit manager (PBM) Magellan Rx Management today announced the launch of an oncology biosimilar program.
Ahead of the anticipated 2019 marketing of FDA-approved anticancer biosimilars in the United States, pharmacy benefit manager (PBM) Magellan Rx Management today announced the launch of an oncology biosimilar program.
The initiative, says the PBM, focuses educating customers, members, and providers “through the implementation of individualized strategies that consider clinical, financial, and regulatory factors.” The result, indicated Magellan, will be to maintain or expand access to effective therapies while delivering savings for its participating customers.
“Magellan Rx is preparing our health plan customers for the upcoming entrance of biosimilars to the oncology category and helping them take advantage of cost savings, while ensuring clinical efficacy and safety, as quickly as possible after the launch of these products,” Kristen Reimers, RPh, senior vice president, specialty clinical solutions, said in a statement. “Our oncology biosimilar initiative takes a multi-pronged approach, including the establishment of plan-specific goals, robust provider education and outreach, and partnership with our customers with the goal to maximize potential savings, minimize disruption, and improve outcomes for patients.”
The PBM says it expects that its new initiative can save $5 million to $8 million per 1 million covered lives, though even more substantial savings may be possible.
The announcement comes close on the heels of Magellan’s recent announcement that its biosimilar management program, which focused on biosimilar infliximab, had resulted in strong biosimilar uptake and significant drug cost savings for health plan organizations during its first year.
According to a statement issued by the PBM in April 2019, the utilization management initiative allowed health plans that took a “comprehensive management approach” (one that switched all patients receiving infliximab for the management of gastroenterological or rheumatological diseases to the biosimilar infliximab Inflectra from the brand-name Remicade) to achieve up to 86% biosimilar use.
Health plans that used a “softer approach,” under which only new patients were asked to use the biosimilar instead of the brand-name Remicade, saw their biosimilar use climb to as high as 75%.
According to Magellan, the switch to biosimilar infliximab saved its health plan members 34% in drug costs for the therapy.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.